Subtopic Deep Dive
ELN Recommendations for AML Diagnosis and Management
Research Guide
What is ELN Recommendations for AML Diagnosis and Management?
ELN Recommendations standardize diagnosis, risk stratification, induction therapy, consolidation, and MRD monitoring for adult AML patients per European LeukemiaNet expert consensus.
The 2017 ELN recommendations by Döhner et al. (Blood, 5711 citations) updated 2010 guidelines with genetic risk categories and MRD integration. Subsequent MRD consensus documents from 2018 (Schuurhuis et al., Blood, 998 citations) and 2021 (Heuser et al., Blood, 651 citations) refined flow cytometry and PCR platforms. Over 20 papers reference these protocols for clinical trials and outcomes.
Why It Matters
ELN guidelines drive standardized AML care, improving survival via risk-adapted therapy; Döhner et al. (2017) classify 40% of patients as favorable risk for reduced-intensity regimens. MRD assessment per Schuurhuis et al. (2018) predicts relapse, guiding consolidation in 70% of trials. Novel agents like venetoclax (Wei et al., 2020, Blood, 717 citations) and ivosidenib (Montesinos et al., 2022, NEJM, 439 citations) integrate into ELN frameworks for older adults, boosting response rates from 20% to 66%.
Key Research Challenges
MRD Platform Standardization
Flow cytometry and qPCR thresholds vary across labs, complicating MRD negativity definitions (Schuurhuis et al., 2018). Heuser et al. (2021) highlight need for harmonized cutoffs in multicenter trials. This delays risk-adapted therapy decisions.
Risk Classification Updates
Genomic subgroups like NPM1/FLT3-ITD challenge 2017 ELN categories (Papaemmanuil et al., 2016). Integrating novel mutations requires prospective validation per Döhner et al. (2017). Older adults face mismatched protocols.
Novel Agent Integration
Incorporating venetoclax and menin inhibitors into induction demands new evidence (Wei et al., 2020; Issa et al., 2023). Dombret and Gardin (2015) note subset-specific tailoring lags behind approvals. Survival gains uneven across mutations.
Essential Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner, Elihu H. Estey, David Grimwade et al. · 2016 · Blood · 5.7K citations
Abstract The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by...
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger et al. · 2016 · New England Journal of Medicine · 4.2K citations
The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification. (Funded by the ...
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit Jan Schuurhuis, Michael Heuser, Sylvie Freeman et al. · 2018 · Blood · 998 citations
Abstract Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for r...
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver, Richard F. Schlenk, Nigel H. Russell et al. · 2019 · Leukemia · 997 citations
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei, Pau Montesinos, Vladimir Ivanov et al. · 2020 · Blood · 717 citations
Abstract Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. Adults age ≥18 years with newly diagnosed AML ineligible ...
Acute myeloid leukemia: current progress and future directions
Hagop M. Kantarjian, Tapan M. Kadia, Courtney D. DiNardo et al. · 2021 · Blood Cancer Journal · 710 citations
Abstract Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. Th...
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Michael Heuser, Sylvie Freeman, Gert J. Ossenkoppele et al. · 2021 · Blood · 651 citations
Abstract Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments. The Euro...
Reading Guide
Foundational Papers
Start with Döhner et al. (2017) for core ELN framework and risk tables; Mrózek et al. (2012) validates cytogenetic reporting system used therein.
Recent Advances
Heuser et al. (2021) for MRD updates; Wei et al. (2020) and Montesinos et al. (2022) for novel agent evidence integrated into protocols.
Core Methods
Risk stratification via cytogenetics/FLT3/NPM1 (Döhner 2017); MRD by multiparameter flow (≥15 markers, Schuurhuis 2018) or RT-qPCR; genomic profiling (WES/RNA-seq, Papaemmanuil 2016).
How PapersFlow Helps You Research ELN Recommendations for AML Diagnosis and Management
Discover & Search
Research Agent uses searchPapers('ELN AML 2022 update') to retrieve Döhner et al. (2017) and citationGraph to map 5000+ citing works on MRD. exaSearch uncovers unpublished ELN drafts; findSimilarPapers links Papaemmanuil et al. (2016) genomic data to guideline evolution.
Analyze & Verify
Analysis Agent runs readPaperContent on Schuurhuis et al. (2018) to extract MRD thresholds, then verifyResponse with CoVe checks guideline adherence in trials. runPythonAnalysis computes survival meta-analysis from Wei et al. (2020) endpoints using pandas; GRADE grades evidence as high for venetoclax integration.
Synthesize & Write
Synthesis Agent detects gaps in ELN for KMT2A rearrangements via Issa et al. (2023), flags contradictions between 2017 and 2021 MRD papers. Writing Agent applies latexEditText for guideline tables, latexSyncCitations for 50 ELN refs, latexCompile for PDF; exportMermaid diagrams risk stratification flowcharts.
Use Cases
"Extract survival data from ELN-cited venetoclax trials and compute pooled HR."
Research Agent → searchPapers('venetoclax AML ELN') → Analysis Agent → readPaperContent(Wei 2020) → runPythonAnalysis(pandas meta-analysis of HR/OR) → researcher gets CSV of pooled 66% CR rate vs 28% placebo.
"Draft LaTeX section comparing 2017 vs 2021 ELN MRD guidelines."
Synthesis Agent → gap detection(Heuser 2021 vs Döhner 2017) → Writing Agent → latexEditText(table diffs) → latexSyncCitations(20 refs) → latexCompile → researcher gets compiled PDF with updated flowcharts.
"Find GitHub repos analyzing ELN risk scores from genomic datasets."
Research Agent → searchPapers('ELN AML genomic') → paperExtractUrls(Papaemmanuil 2016) → paperFindGithubRepo → githubRepoInspect → researcher gets 3 repos with R scripts for ELN classifier validation.
Automated Workflows
Deep Research workflow scans 50+ ELN-citing papers via searchPapers → citationGraph → structured report on MRD evolution (Schuurhuis 2018 to Heuser 2021). DeepScan applies 7-step CoVe to verify novel agent integration in Döhner framework. Theorizer generates hypotheses for ELN updates from Papaemmanuil genomic clusters.
Frequently Asked Questions
What defines ELN risk categories in AML?
2017 ELN by Döhner et al. stratifies into favorable (t(8;21), inv(16), npm1 wild/FLT3-ITD low), intermediate, adverse (complex karyotype, TP53 mut); updated for MRD negativity.
What MRD methods does ELN recommend?
Flow cytometry (≥10^-3 sensitivity) and qPCR for RUNX1-RUNX1T1/CBFB-MYH11 per Schuurhuis et al. (2018); 2021 update by Heuser et al. adds NGS for 20-30% coverage.
Which key papers establish ELN guidelines?
Foundational: Döhner et al. (2017, Blood, 5711 cites); MRD: Schuurhuis (2018), Heuser (2021); genomic basis: Papaemmanuil (2016, NEJM, 4182 cites).
What open problems remain in ELN AML protocols?
Standardizing MRD across mutations beyond NPM1; integrating menin inhibitors (Issa 2023); prospective validation for venetoclax in fit elderly (Wei 2020).
Research Acute Myeloid Leukemia Research with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching ELN Recommendations for AML Diagnosis and Management with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
Part of the Acute Myeloid Leukemia Research Research Guide